Navigation Links
Metabolomx Awarded $1.14 Million SBIR Grant from National Cancer Institute for Breath Analysis Test of Lung Cancer
Date:10/24/2011

MOUNTAIN VIEW, Calif., Oct. 24, 2011 /PRNewswire/ -- Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, today announced the Company was awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined Phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

Metabolomx' proprietary technology is designed to recognize the molecular fingerprint of lung cancer via a sampling of metabolites (volatile organic compounds) in exhaled breath. The Company's system currently is being evaluated in a large lung cancer screening study at the Cleveland Clinic.

Paul Rhodes, Ph.D., Founder and CEO of Metabolomx, commented, "The core insight of Metabolomx is that the pattern of small-molecule metabolites produced by active tumors can be observed in exhaled breath. Because our system is rapid, non-invasive and inexpensive, we believe it can be both a timely adjunct diagnostic following an indeterminate CT scan and, in the future, can help facilitate earlier diagnosis of disease. This is particularly critical in lung cancer, since many patients are first diagnosed only late in their disease."

Dr. Rhodes continued, "We are grateful for the support of the NCI grant, which will help us to further validate our technology and advance the breakthrough studies of our breath analysis system for lung cancer, breast cancer, colon cancer and other cancers."

About Metabolomx

Metabolomx has developed and owns all worldwide rights to the foremost breath test for cancer. By engaging some of the brightest minds in the fields of artificial and biological olfactory sensor arrays, neural processing and product development, Metabolomx has developed and tested an artificial olfactory sensor technology that recognizes the molecular fingerprint of the disease signature in breath. Metabolomx' technology is enabling the non-invasive, rapid, inexpensive and early diagnosis of lung cancer and other cancers. Metabolomx is located in Mountain View, CA. For additional information on the Company, please visit www.metabolomx.com.

Contacts

Media              
Justin Jackson              
Michelle Szwarcberg              
Burns McClellan              
Tel: +1-212-213-0006              
Email: jjackson@burnsmc.com                
mszwarcberg@burnsmc.com


'/>"/>
SOURCE Metabolomx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Dr. Yong Shi awarded NSF grant
3. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
7. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
8. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
9. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
10. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
11. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid ... pleased to announce that it has moved into a new, 5000 sqft, purpose-built, ... the new facility demonstrates the company's continuous commitment to quality research and service ...
(Date:9/24/2019)... ... 2019 , ... Drug resistance has been declared as one of the biggest ... one of the most serious concerns. Hong Kong cannot be spared from the worsening ... or a seven-fold of the figure in 2007 – the year the disease became ...
(Date:9/24/2019)... ... ... In the past three years, the National Science Foundation (NSF) has awarded ... of Mines & Technology that expands human understanding of the microbial world. The ... and yet strong layer which is commonly known as a biofilm. , The broad ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a Rochester ... today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office ... class recommendations for hypertension treatment. , The patent applies to Geneticure’s first ...
Breaking Biology Technology:
(Date:10/3/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, ... stem cell treatment of knee osteoarthritis . The successful enrollment comes only a little ... Biopharma. , PSC CEO, Michael Dale, stated, “We are proud that as we celebrate ...
(Date:9/30/2019)... ALTO, Calif. (PRWEB) , ... September 30, 2019 ... ... public interest organization focused on molecular manufacturing and other transformative technologies, announced the ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem cells (hiPSCs) ... the development and diseases of the human heart, there is an increasing need for ... muscle cells to be clearly and easily recorded. A study released today in STEM ...
Breaking Biology News(10 mins):